Answer:
During the asexual reproduction, bacteria can divide simply by binary fission in which one bacteria first replicate its genetic material and the cell divide in two daughter cells which are identical to the parent cell.
Asexual reproduction does not allow genetic variation therefore to get genetic variation bacteria can use conjugation, transformation and transduction process.
In conjugation, bacteria gets extra genetic material from other bacteria through sex pills. In transduction the genetic material enters into the bacterial cell through the virus then bacteria incorporate this genetic material in its genome.
In transformation, bacteria takes up the extra genetic material from it's surrounding. Therefore conjugation, transduction, and transformation helps bacterial to gain variation like as in sexual reproduction.
Answer:
GM is a technology that involves inserting DNA into the genome of an organism. To produce a GM plant, new DNA is transferred into plant cells. Usually, the cells are then grown in tissue culture where they develop into plants. The seeds produced by these plants will inherit the new DNA.
Explanation:
Answer:
A scale and a tape measure.
Explanation:
Use the tape measure to get the volume and the scale to get the mass.
The correct answer is C. The right side of the heart delivers deoxygenated blood (from vena cava) to the lungs (via pulmonary artery)
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
